217 related articles for article (PubMed ID: 23478308)
1. Prediction of mild cognitive impairment that evolves into Alzheimer's disease dementia within two years using a gene expression signature in blood: a pilot study.
Roed L; Grave G; Lindahl T; Rian E; Horndalsveen PO; Lannfelt L; Nilsson C; Swenson F; Lönneborg A; Sharma P; Sjögren M
J Alzheimers Dis; 2013; 35(3):611-21. PubMed ID: 23478308
[TBL] [Abstract][Full Text] [Related]
2. The validity of amnestic MCI and non-amnestic MCI at age 75 in the prediction of Alzheimer's dementia and vascular dementia.
Jungwirth S; Zehetmayer S; Hinterberger M; Tragl KH; Fischer P
Int Psychogeriatr; 2012 Jun; 24(6):959-66. PubMed ID: 22300486
[TBL] [Abstract][Full Text] [Related]
3. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI.
Vos SJ; van Rossum IA; Verhey F; Knol DL; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Frisoni GB; Froelich L; Nobili F; van der Flier W; Blennow K; Wolz R; Scheltens P; Visser PJ
Neurology; 2013 Mar; 80(12):1124-32. PubMed ID: 23446677
[TBL] [Abstract][Full Text] [Related]
4. Impact of Depressive Symptoms on Conversion from Mild Cognitive Impairment Subtypes to Alzheimer's Disease: A Community-Based Longitudinal Study.
Kida J; Nemoto K; Ikejima C; Bun S; Kakuma T; Mizukami K; Asada T
J Alzheimers Dis; 2016; 51(2):405-15. PubMed ID: 26890740
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of hippocampal volume and serum brain-derived neurotrophic factor as potential diagnostic markers of conversion from amnestic mild cognitive impairment to Alzheimer disease: A STROBE-compliant article.
Fang Y; Du N; Xing L; Duo Y; Zheng L
Medicine (Baltimore); 2019 Jul; 98(30):e16604. PubMed ID: 31348306
[TBL] [Abstract][Full Text] [Related]
6. Sustainable method for Alzheimer dementia prediction in mild cognitive impairment: Electroencephalographic connectivity and graph theory combined with apolipoprotein E.
Vecchio F; Miraglia F; Iberite F; Lacidogna G; Guglielmi V; Marra C; Pasqualetti P; Tiziano FD; Rossini PM
Ann Neurol; 2018 Aug; 84(2):302-314. PubMed ID: 30014515
[TBL] [Abstract][Full Text] [Related]
7. Generalizability of the disease state index prediction model for identifying patients progressing from mild cognitive impairment to Alzheimer's disease.
Hall A; Muñoz-Ruiz M; Mattila J; Koikkalainen J; Tsolaki M; Mecocci P; Kloszewska I; Vellas B; Lovestone S; Visser PJ; Lötjonen J; Soininen H; ; ;
J Alzheimers Dis; 2015; 44(1):79-92. PubMed ID: 25201784
[TBL] [Abstract][Full Text] [Related]
8. Multiomics Blood-Based Biomarkers Predict Alzheimer's Predementia with High Specificity in a Multicentric Cohort Study.
Souchet B; Michaïl A; Heuillet M; Dupuy-Gayral A; Haudebourg E; Pech C; Berthemy AA; Autelitano F; Billoir B; Domoto-Reilly K; Fowler C; Grabowski T; Jayadev S; Masters CL; Braudeau J
J Prev Alzheimers Dis; 2024; 11(3):567-581. PubMed ID: 38706273
[TBL] [Abstract][Full Text] [Related]
9. Screening and treatment for Alzheimer's disease: predicting population-level outcomes.
Furiak NM; Kahle-Wrobleski K; Callahan C; Klein TM; Klein RW; Siemers ER
Alzheimers Dement; 2012 Jan; 8(1):31-8. PubMed ID: 22265589
[TBL] [Abstract][Full Text] [Related]
10. Searching for Primary Predictors of Conversion from Mild Cognitive Impairment to Alzheimer's Disease: A Multivariate Follow-Up Study.
López ME; Turrero A; Cuesta P; López-Sanz D; Bruña R; Marcos A; Gil P; Yus M; Barabash A; Cabranes JA; Maestú F; Fernández A
J Alzheimers Dis; 2016 Mar; 52(1):133-43. PubMed ID: 27060953
[TBL] [Abstract][Full Text] [Related]
11. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.
Yu P; Dean RA; Hall SD; Qi Y; Sethuraman G; Willis BA; Siemers ER; Martenyi F; Tauscher JT; Schwarz AJ
J Alzheimers Dis; 2012; 32(2):373-85. PubMed ID: 22796873
[TBL] [Abstract][Full Text] [Related]
12. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
[TBL] [Abstract][Full Text] [Related]
13. Prediction of Outcomes in Mild Cognitive Impairment by Using 18F-FDG-PET: A Multicenter Study.
Ito K; Fukuyama H; Senda M; Ishii K; Maeda K; Yamamoto Y; Ouchi Y; Ishii K; Okumura A; Fujiwara K; Kato T; Arahata Y; Washimi Y; Mitsuyama Y; Meguro K; Ikeda M;
J Alzheimers Dis; 2015; 45(2):543-52. PubMed ID: 25589723
[TBL] [Abstract][Full Text] [Related]
14. Validating the role of the Australian National University Alzheimer's Disease Risk Index (ANU-ADRI) and a genetic risk score in progression to cognitive impairment in a population-based cohort of older adults followed for 12 years.
Andrews SJ; Eramudugolla R; Velez JI; Cherbuin N; Easteal S; Anstey KJ
Alzheimers Res Ther; 2017 Mar; 9(1):16. PubMed ID: 28259165
[TBL] [Abstract][Full Text] [Related]
15. Quantitative evaluation of disease progression in a longitudinal mild cognitive impairment cohort.
Runtti H; Mattila J; van Gils M; Koikkalainen J; Soininen H; Lötjönen J;
J Alzheimers Dis; 2014; 39(1):49-61. PubMed ID: 24121959
[TBL] [Abstract][Full Text] [Related]
16. A blood-based, 7-metabolite signature for the early diagnosis of Alzheimer's disease.
Olazarán J; Gil-de-Gómez L; Rodríguez-Martín A; Valentí-Soler M; Frades-Payo B; Marín-Muñoz J; Antúnez C; Frank-García A; Acedo-Jiménez C; Morlán-Gracia L; Petidier-Torregrossa R; Guisasola MC; Bermejo-Pareja F; Sánchez-Ferro Á; Pérez-Martínez DA; Manzano-Palomo S; Farquhar R; Rábano A; Calero M
J Alzheimers Dis; 2015; 45(4):1157-73. PubMed ID: 25649659
[TBL] [Abstract][Full Text] [Related]
17. Effects of a newly developed cognitive intervention in amnestic mild cognitive impairment and mild Alzheimer's disease: a pilot study.
Buschert VC; Friese U; Teipel SJ; Schneider P; Merensky W; Rujescu D; Möller HJ; Hampel H; Buerger K
J Alzheimers Dis; 2011; 25(4):679-94. PubMed ID: 21483095
[TBL] [Abstract][Full Text] [Related]
18. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].
Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ;
Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080
[TBL] [Abstract][Full Text] [Related]
19. Role of cerebrospinal fluid biomarkers to predict conversion to dementia in patients with mild cognitive impairment: a clinical cohort study.
Tondelli M; Bedin R; Chiari A; Molinari MA; Bonifacio G; Lelli N; Trenti T; Nichelli P
Clin Chem Lab Med; 2015 Feb; 53(3):453-60. PubMed ID: 25274948
[TBL] [Abstract][Full Text] [Related]
20. Leukocyte telomere length (LTL) is reduced in stable mild cognitive impairment but low LTL is not associated with conversion to Alzheimer's disease: a pilot study.
Movérare-Skrtic S; Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Zetterberg H; Blennow K; Svensson J
Exp Gerontol; 2012 Feb; 47(2):179-82. PubMed ID: 22210159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
